Galcanezumab for Vestibular Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
Vestibular Migraine
Interventions
DRUG

Galcanezumab Prefilled Syringe

Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.

DRUG

Placebo

Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.

Trial Locations (1)

94115

UCSF Medical Center at Mount Zion, San Francisco

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT04417361 - Galcanezumab for Vestibular Migraine | Biotech Hunter | Biotech Hunter